CD70特异性CAR T细胞对急性髓系白血病有强活性且无造血干细胞毒性
该研究针对急性髓系白血病(AML)缺乏肿瘤特异性靶点的问题,开发了靶向CD70的CAR T细胞。比较不同结构CD70scFv CAR与CD27z CAR后,发现CD27z CAR在体外和体内均表现出更优的增殖和抗肿瘤活性。CD70-CAR T细胞可识别表达CD70的活化病毒特异性T细胞,但不影响正常造血干细胞集落形成。
要点
- CD27z CAR T细胞在增殖和抗肿瘤活性上优于所有CD70scFv CAR T细胞。
- CD70-CAR T细胞不影响正常造血干细胞集落形成,但需监测病毒特异性T细胞反应。
核心结论
- CD70靶向免疫治疗是CD70阳性AML的有前景新策略,不影响正常造血但需监测病毒特异性T细胞反应。
研究设计与样本
- 研究生成了一系列CD70-CAR T细胞,包含共同scFv但胞外间隔区、跨膜和共刺激域不同,并与含人CD27融合CD3ζ链的CD27z CAR比较。
主要发现
- CAR结构组成强烈影响CD70scFv CAR T细胞的表达水平、活力、扩增和细胞毒能力。
- CD27z-CAR T细胞在体外和体内均表现出优于所有CD70scFv-CAR T细胞的增殖和抗肿瘤活性。
- CD70-CAR T细胞可识别表达CD70的活化病毒特异性T细胞。
- CD70-CAR T细胞不阻止正常造血干细胞的集落形成。
临床怎么用
- CD70靶向CAR T细胞可用于CD70阳性AML患者,但治疗期间需监测病毒特异性T细胞反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of patients with acute myeloid leukemia (AML) remains dismal, highlighting the need for novel innovative treatment strategies. The application of chimeric antigen receptor (CAR) T-cell therapy to patients with AML has been limited, in particular by the lack of a tumor-specific target antigen. CD70 is a promising antigen to target AML, as it is expressed on most leukemic blasts, whereas little or no expression is detectable in normal bone marrow samples. To target CD70 on AML cells, we generated a panel of CD70-CAR T cells that contained a common single-chain variable fragment (scFv) for antigen detection, but differed in size and flexibility of the extracellular spacer and in the transmembrane and the costimulatory domains. These CD70scFv CAR T cells were compared with a CAR construct that contained human CD27, the ligand of CD70 fused to the CD3ζ chain (CD27z). The structural composition of the CAR strongly influenced expression levels, viability, expansion, and cytotoxic capacities of CD70scFv-based CAR T cells, but CD27z-CAR T cells demonstrated superior proliferation and antitumor activity in vitro and in vivo, compared with all CD70scFv-CAR T cells. Although CD70-CAR T cells recognized activated virus-specific T cells (VSTs) that expressed CD70, they did not prevent colony formation by normal hematopoietic stem cells. Thus, CD70-targeted immunotherapy is a promising new treatment strategy for patients with CD70-positive AML that does not affect normal hematopoiesis but will require monitoring of virus-specific T-cell responses.
引用
- Sauer T, Parikh K, Sharma S, et al. CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 2021. PMID: 34323938. doi:10.1182/blood.2020008221
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。